Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 14/20 | 0.80 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.62 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.54 |
| ▸ | CDK2 | P24941 | 3/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.54 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.54 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.54 |
| ▸ | CDK9 | P50750 | 2/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4691713 | 0.89 | FYN (0.79) | FYNPIK3CGMKNK1ALDH1A1HPGD | |
| SCHEMBL2946665 | 0.89 | FYN (0.83) | FYNPIK3CGMKNK1 | |
| SCHEMBL13234408 | 0.89 | FYN (1.00) | FYNPIK3CGMKNK1ALDH1A1HPGD | |
| SCHEMBL1054837 | 0.84 | FYN (0.83) | FYNPIK3CGMKNK1ALDH1A1HPGD | |
| SCHEMBL2941576 | 0.84 | FYN (0.78) | FYNPIK3CGMKNK1 | |
| SCHEMBL2944474 | 0.83 | FYN (0.81) | FYNPIK3CGMKNK1 | |
| SCHEMBL1053480 | 0.83 | FYN (1.00) | FYNPIK3CGMKNK1 | |
| SCHEMBL2951386 | 0.82 | FYN (0.80) | FYNPIK3CG | |
| SCHEMBL2944482 | 0.82 | FYN (1.00) | FYNPIK3CG | |
| SCHEMBL2948460 | 0.82 | FYN (0.82) | FYNPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1900739-A1 | Diazolodiazine derivatives as kinase inhibitors | CELLZOME AG (DE) | 2008-03-19 | — | — | EP | claimed |
| WO-2008025822-A1 | DIAZOLODIAZINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | claimed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| EP-1900739-A1 | Diazolodiazine derivatives as kinase inhibitors | CELLZOME AG (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2008025822-A1 | DIAZOLODIAZINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | FYN 421/4885PIK3CG 138/4885DYRK3 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.